Literature DB >> 9438028

From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor.

B Rist1, M Entzeroth, A G Beck-Sickinger.   

Abstract

CGRP Y0-28-37 is known as a selective CGRP1 receptor antagonist. In order to elucidate the essential requirements for its receptor interaction, we performed a variety of systematic approaches by modifying the C-terminal segments CGRP Y0-28-37 and CGRP 27-37. N-Terminal and C-terminal segments have been synthesized, as well as chimeras which combine segments of CGRP, adrenomedullin, and amylin. Furthermore, we carried out an Ala scan, a Phe scan, a D-amino acid scan and a Pro scan of CGRP 27-37. Additionally, single amino acids were replaced by those with similar biophysical properties. Receptor binding studies of all analogs were performed at human neuroblastoma cells SK-N-MC, which selectively express the hCGRP1 receptor. On the basis of the obtained results, we synthesized a series of ligands with multiple amino acid replacements in order to optimize the exchange at each position. This approach yielded to a series of high affinity ligands, including [D31,P34,F35] CGRP 27-37 which exhibits a 100-fold increased affinity compared to the unmodified segment. So far, this is the smallest CGRP analog that shows affinity in the nanomolar range.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9438028     DOI: 10.1021/jm970533r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Metabolic cleavage of cell-penetrating peptides in contact with epithelial models: human calcitonin (hCT)-derived peptides, Tat(47-57) and penetratin(43-58).

Authors:  Rachel Tréhin; Hanne M Nielsen; Heinz-Georg Jahnke; Ulrike Krauss; Annette G Beck-Sickinger; Hans P Merkle
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

2.  Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat(47-57) through well-differentiated epithelial models.

Authors:  Rachel Tréhin; Ulrike Krauss; Annette G Beck-Sickinger; Hans P Merkle; Hanne M Nielsen
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

3.  Cellular internalization of human calcitonin derived peptides in MDCK monolayers: a comparative study with Tat(47-57) and penetratin(43-58).

Authors:  Rachel Tréhin; Ulrike Krauss; Roman Muff; Martina Meinecke; Annette G Beck-Sickinger; Hans P Merkle
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

4.  Selective CGRP and adrenomedullin peptide binding by tethered RAMP-calcitonin receptor-like receptor extracellular domain fusion proteins.

Authors:  Heather E Moad; Augen A Pioszak
Journal:  Protein Sci       Date:  2013-10-19       Impact factor: 6.725

5.  Identification of key residues involved in adrenomedullin binding to the AM1 receptor.

Authors:  H A Watkins; M Au; R Bobby; J K Archbold; N Abdul-Manan; J M Moore; M J Middleditch; G M Williams; M A Brimble; A J Dingley; D L Hay
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 6.  Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.

Authors:  Debbie L Hay; Augen A Pioszak
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

7.  Calcitonin and Amylin Receptor Peptide Interaction Mechanisms: INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS.

Authors:  Sang-Min Lee; Debbie L Hay; Augen A Pioszak
Journal:  J Biol Chem       Date:  2016-02-19       Impact factor: 5.157

8.  Conformational restraints revealing bioactive beta-bend structures for halpha CGRP8-37 at the CGRP2 receptor of the rat prostatic vas deferens.

Authors:  F M Wisskirchen; P M Doyle; S L Gough; C J Harris; I Marshall
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 9.  Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.

Authors:  Debbie L Hay; Michael L Garelja; David R Poyner; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-11-28       Impact factor: 8.739

10.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.